Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2

Hiroshi Mochimaru, Norihiro Nagai, Go Hasegawa, Chie Kudo-Saito, Tomonori Yaguchi, Yoshihiko Usui, Toshihide Kurihara, Takashi Koto, Shingo Satojuka, Hajime Shinoda, Yoko Ozawa, Kazuo Tsubota, Yutaka Kawakami, Susumu Ishida

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

PURPOSE. To investigate whether the induction of cellular immunity against vascular endothelial growth factor receptor (VEGFR) 2 inhibits the development of choroidal neovascularization (CNV). METHODS. H-2Db-restricted peptide corresponding to amino acids 400 to 408 of VEGFR2 was used as an epitope peptide. Dendritic cells (DCs) were harvested from bone marrow progenitors of C57BL/6 mice. Six-week-old C57BL/6 mice received subcutaneous injections of the epitope peptide-pulsed mature DCs three times at 6-day intervals. After the third immunization, laser photocoagulation was performed to induce CNV. One week after photocoagulation, mice were killed to harvest the choroid and splenocytes. CNV volume was evaluated by volumetric measurements. To confirm the specific immunogenicity of the epitope peptides in C57BL/6 mice, CD8 T cells isolated from harvested splenocytes were restimulated to measure interferon (IFN)-γ and tumor necrosis factor (TNF)-α production through enzyme-linked immunospot assay and ELISA. To determine the T-cell subset responsible for the immunotherapy, mice were intraperitoneally injected with an anti-CD4 or anti-CD8 depletion antibody. RESULTS. CNV volume was significantly lower in mice immunized with the VEGFR2 epitope peptide than in those not immunized or immunized with a control peptide gp70. Cytokine assays showed the peptide-specific production of IFN-γ and TNF-α from the CD8 T cells in a dose-dependent manner. In vivo depletion of CD8, but not CD4, T cells significantly reversed the suppressive effect of the VEGFR2 peptide-pulsed DC vaccination on CNV to the level observed in nonimmunized or gp70-immunized animals. CONCLUSIONS. These results indicate that the VEGFR2 peptide-specific induction of cellular immunity inhibits CNV through the cytotoxicity of CD8 T cells. Results of the present study suggested the possibility of DC vaccination targeting VEGFR2 as a novel therapeutic strategy for CNV.

Original languageEnglish
Pages (from-to)4795-4801
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume48
Issue number10
DOIs
Publication statusPublished - 2007 Oct

Fingerprint

Choroidal Neovascularization
Dendritic Cells
Vaccination
Peptides
Epitopes
Inbred C57BL Mouse
T-Lymphocytes
Light Coagulation
Cellular Immunity
Interferons
Tumor Necrosis Factor-alpha
Enzyme-Linked Immunospot Assay
Vascular Endothelial Growth Factor Receptor-2
Choroid
T-Lymphocyte Subsets
Subcutaneous Injections
Immunotherapy
Immunization
Lasers
Bone Marrow

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2. / Mochimaru, Hiroshi; Nagai, Norihiro; Hasegawa, Go; Kudo-Saito, Chie; Yaguchi, Tomonori; Usui, Yoshihiko; Kurihara, Toshihide; Koto, Takashi; Satojuka, Shingo; Shinoda, Hajime; Ozawa, Yoko; Tsubota, Kazuo; Kawakami, Yutaka; Ishida, Susumu.

In: Investigative Ophthalmology and Visual Science, Vol. 48, No. 10, 10.2007, p. 4795-4801.

Research output: Contribution to journalArticle

Mochimaru, H, Nagai, N, Hasegawa, G, Kudo-Saito, C, Yaguchi, T, Usui, Y, Kurihara, T, Koto, T, Satojuka, S, Shinoda, H, Ozawa, Y, Tsubota, K, Kawakami, Y & Ishida, S 2007, 'Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2', Investigative Ophthalmology and Visual Science, vol. 48, no. 10, pp. 4795-4801. https://doi.org/10.1167/iovs.07-0425
Mochimaru, Hiroshi ; Nagai, Norihiro ; Hasegawa, Go ; Kudo-Saito, Chie ; Yaguchi, Tomonori ; Usui, Yoshihiko ; Kurihara, Toshihide ; Koto, Takashi ; Satojuka, Shingo ; Shinoda, Hajime ; Ozawa, Yoko ; Tsubota, Kazuo ; Kawakami, Yutaka ; Ishida, Susumu. / Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2. In: Investigative Ophthalmology and Visual Science. 2007 ; Vol. 48, No. 10. pp. 4795-4801.
@article{b35e6787da93491fa5e8c7767f434a33,
title = "Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2",
abstract = "PURPOSE. To investigate whether the induction of cellular immunity against vascular endothelial growth factor receptor (VEGFR) 2 inhibits the development of choroidal neovascularization (CNV). METHODS. H-2Db-restricted peptide corresponding to amino acids 400 to 408 of VEGFR2 was used as an epitope peptide. Dendritic cells (DCs) were harvested from bone marrow progenitors of C57BL/6 mice. Six-week-old C57BL/6 mice received subcutaneous injections of the epitope peptide-pulsed mature DCs three times at 6-day intervals. After the third immunization, laser photocoagulation was performed to induce CNV. One week after photocoagulation, mice were killed to harvest the choroid and splenocytes. CNV volume was evaluated by volumetric measurements. To confirm the specific immunogenicity of the epitope peptides in C57BL/6 mice, CD8 T cells isolated from harvested splenocytes were restimulated to measure interferon (IFN)-γ and tumor necrosis factor (TNF)-α production through enzyme-linked immunospot assay and ELISA. To determine the T-cell subset responsible for the immunotherapy, mice were intraperitoneally injected with an anti-CD4 or anti-CD8 depletion antibody. RESULTS. CNV volume was significantly lower in mice immunized with the VEGFR2 epitope peptide than in those not immunized or immunized with a control peptide gp70. Cytokine assays showed the peptide-specific production of IFN-γ and TNF-α from the CD8 T cells in a dose-dependent manner. In vivo depletion of CD8, but not CD4, T cells significantly reversed the suppressive effect of the VEGFR2 peptide-pulsed DC vaccination on CNV to the level observed in nonimmunized or gp70-immunized animals. CONCLUSIONS. These results indicate that the VEGFR2 peptide-specific induction of cellular immunity inhibits CNV through the cytotoxicity of CD8 T cells. Results of the present study suggested the possibility of DC vaccination targeting VEGFR2 as a novel therapeutic strategy for CNV.",
author = "Hiroshi Mochimaru and Norihiro Nagai and Go Hasegawa and Chie Kudo-Saito and Tomonori Yaguchi and Yoshihiko Usui and Toshihide Kurihara and Takashi Koto and Shingo Satojuka and Hajime Shinoda and Yoko Ozawa and Kazuo Tsubota and Yutaka Kawakami and Susumu Ishida",
year = "2007",
month = "10",
doi = "10.1167/iovs.07-0425",
language = "English",
volume = "48",
pages = "4795--4801",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "10",

}

TY - JOUR

T1 - Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2

AU - Mochimaru, Hiroshi

AU - Nagai, Norihiro

AU - Hasegawa, Go

AU - Kudo-Saito, Chie

AU - Yaguchi, Tomonori

AU - Usui, Yoshihiko

AU - Kurihara, Toshihide

AU - Koto, Takashi

AU - Satojuka, Shingo

AU - Shinoda, Hajime

AU - Ozawa, Yoko

AU - Tsubota, Kazuo

AU - Kawakami, Yutaka

AU - Ishida, Susumu

PY - 2007/10

Y1 - 2007/10

N2 - PURPOSE. To investigate whether the induction of cellular immunity against vascular endothelial growth factor receptor (VEGFR) 2 inhibits the development of choroidal neovascularization (CNV). METHODS. H-2Db-restricted peptide corresponding to amino acids 400 to 408 of VEGFR2 was used as an epitope peptide. Dendritic cells (DCs) were harvested from bone marrow progenitors of C57BL/6 mice. Six-week-old C57BL/6 mice received subcutaneous injections of the epitope peptide-pulsed mature DCs three times at 6-day intervals. After the third immunization, laser photocoagulation was performed to induce CNV. One week after photocoagulation, mice were killed to harvest the choroid and splenocytes. CNV volume was evaluated by volumetric measurements. To confirm the specific immunogenicity of the epitope peptides in C57BL/6 mice, CD8 T cells isolated from harvested splenocytes were restimulated to measure interferon (IFN)-γ and tumor necrosis factor (TNF)-α production through enzyme-linked immunospot assay and ELISA. To determine the T-cell subset responsible for the immunotherapy, mice were intraperitoneally injected with an anti-CD4 or anti-CD8 depletion antibody. RESULTS. CNV volume was significantly lower in mice immunized with the VEGFR2 epitope peptide than in those not immunized or immunized with a control peptide gp70. Cytokine assays showed the peptide-specific production of IFN-γ and TNF-α from the CD8 T cells in a dose-dependent manner. In vivo depletion of CD8, but not CD4, T cells significantly reversed the suppressive effect of the VEGFR2 peptide-pulsed DC vaccination on CNV to the level observed in nonimmunized or gp70-immunized animals. CONCLUSIONS. These results indicate that the VEGFR2 peptide-specific induction of cellular immunity inhibits CNV through the cytotoxicity of CD8 T cells. Results of the present study suggested the possibility of DC vaccination targeting VEGFR2 as a novel therapeutic strategy for CNV.

AB - PURPOSE. To investigate whether the induction of cellular immunity against vascular endothelial growth factor receptor (VEGFR) 2 inhibits the development of choroidal neovascularization (CNV). METHODS. H-2Db-restricted peptide corresponding to amino acids 400 to 408 of VEGFR2 was used as an epitope peptide. Dendritic cells (DCs) were harvested from bone marrow progenitors of C57BL/6 mice. Six-week-old C57BL/6 mice received subcutaneous injections of the epitope peptide-pulsed mature DCs three times at 6-day intervals. After the third immunization, laser photocoagulation was performed to induce CNV. One week after photocoagulation, mice were killed to harvest the choroid and splenocytes. CNV volume was evaluated by volumetric measurements. To confirm the specific immunogenicity of the epitope peptides in C57BL/6 mice, CD8 T cells isolated from harvested splenocytes were restimulated to measure interferon (IFN)-γ and tumor necrosis factor (TNF)-α production through enzyme-linked immunospot assay and ELISA. To determine the T-cell subset responsible for the immunotherapy, mice were intraperitoneally injected with an anti-CD4 or anti-CD8 depletion antibody. RESULTS. CNV volume was significantly lower in mice immunized with the VEGFR2 epitope peptide than in those not immunized or immunized with a control peptide gp70. Cytokine assays showed the peptide-specific production of IFN-γ and TNF-α from the CD8 T cells in a dose-dependent manner. In vivo depletion of CD8, but not CD4, T cells significantly reversed the suppressive effect of the VEGFR2 peptide-pulsed DC vaccination on CNV to the level observed in nonimmunized or gp70-immunized animals. CONCLUSIONS. These results indicate that the VEGFR2 peptide-specific induction of cellular immunity inhibits CNV through the cytotoxicity of CD8 T cells. Results of the present study suggested the possibility of DC vaccination targeting VEGFR2 as a novel therapeutic strategy for CNV.

UR - http://www.scopus.com/inward/record.url?scp=35748974523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748974523&partnerID=8YFLogxK

U2 - 10.1167/iovs.07-0425

DO - 10.1167/iovs.07-0425

M3 - Article

VL - 48

SP - 4795

EP - 4801

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 10

ER -